Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update

被引：83

作者：

Greinacher, Andreas

Warkentin, Theodore E.

机构：

[1] Univ Greifswald, Inst Immunol & Transfus Med, D-17489 Greifswald, Germany

[2] McMaster Univ, Hamilton, ON, Canada

[3] Hamilton Hlth Sci, Hamilton, ON, Canada

来源：

THROMBOSIS RESEARCH | 2006年 / 118卷 / 02期

关键词：

heparin-induced thrombocytopenia; direct thrombin inhibitor; unfractionated heparin; platelets; PF4;

D O I：

10.1016/j.thromres.2005.07.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heparin-induced thrombocytopenia (HIT) is one of the most important life- and timb-threatening adverse drug events encountered by physicians. Serious sequelae associated with HIT can be avoided with early recognition and appropriate treatment. This review examines the recommendations published in 2004 by the American College of Chest Physicians on the recognition, treatment, and prevention of HIT together with more recent data, especially regarding treatment with direct thrombin inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：165 / 176

页数：12

相关论文

共 38 条

[1] HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS [J].

ASTER, RH .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1374-1376

[2]

*BERL LAB, 2002, REFLUDAN

[3] Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery [J].

Francis, JL ;

Palmer, GJ ;

Moroose, R ;

Drexler, A .

ANNALS OF THORACIC SURGERY, 2003, 75 (01) :17-22

[4] The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study [J].

Girolami, B ;

Prandoni, P ;

Stefani, PM ;

Tanduo, C ;

Sabbion, P ;

Eichler, P ;

Ramon, R ;

Baggio, G ;

Fabris, F ;

Girolami, A .

BLOOD, 2003, 101 (08) :2955-2959

[5]

*GLAXOSMITHKLINE, 2003, ARGATROBAN

[6] Comparing direct thrombin inhibitors using aPTT ecarin clotting times, and thrombin inhibitor management testing [J].

Gosselin, RC ;

King, JH ;

Janatpour, KA ;

Dager, WE ;

Larkin, EC ;

Owings, JT .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) :1383-1388

[7] Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values [J].

Gosselin, RC ;

Dager, WE ;

King, JH ;

Janatpour, K ;

Mahackian, K ;

Larkin, EC ;

Owings, JT .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (04) :593-599

[8] Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range [J].

Greinacher, A ;

Eichler, P ;

Lubenow, N ;

Kwasny, H ;

Luz, M .

BLOOD, 2000, 96 (03) :846-851

[9] Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia [J].

Greinacher, A ;

Lubenow, N ;

Eichler, P .

CIRCULATION, 2003, 108 (17) :2062-2065

[10] LABORATORY DIAGNOSIS OF HEPARIN-ASSOCIATED THROMBOCYTOPENIA AND COMPARISON OF PLATELET-AGGREGATION TEST, HEPARIN-INDUCED PLATELET ACTIVATION TEST, AND PLATELET FACTOR-4 HEPARIN ENZYME-LINKED-IMMUNOSORBENT-ASSAY [J].

GREINACHER, A ;

AMIRAL, J ;

DUMMEL, V ;

VISSAC, A ;

KIEFEL, V ;

MUELLERECKHARDT, C .

TRANSFUSION, 1994, 34 (05) :381-385

← 1 2 3 4 →